Schedule 13G ownership disclosure
CRISPR Therapeutics AG
Common Stock · CUSIP: H17182108
Event date: 2025-12-31
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- ORBIS INVESTMENT MANAGEMENT LTD
Shares: 5,934,328 · Class: 6.2%
- Allan Gray Australia Pty Ltd
Shares: 15,817 · Class: 0%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0000940594-26-000006
- Form type
- SCHEDULE 13G/A
- Filer
- CRISPR Therapeutics AG
- CIK
- CIK 1674416
- Filed
- Feb 17, 2026
- Reporting period
- Dec 31, 2025
- Description
- Schedule 13G beneficial ownership